Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug 1;18(8):991-993.
doi: 10.2215/CJN.0000000000000232. Epub 2023 Jul 7.

Extending SGLT2 Inhibitor Use for People Undergoing Dialysis?

Wendy L St Peter  1 , Calvin J Meaney  2
Affiliations
Editorial

Extending SGLT2 Inhibitor Use for People Undergoing Dialysis?

Wendy L St Peter et al. Clin J Am Soc Nephrol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

C.J. Meaney reports consultancy for Wolters-Kluwer (Lexicomp) and advisory or leadership role for GSK Advisory Board. W.L. St. Peter reports consultancy for Bayer, Boerhringer-Ingelheim-Lilly, CSL-Vifor Pharma, GSK, and Total Renal Care, Inc.; advisory or leadership role as Scientific Advisory Board Member for National Kidney Foundation; and other interests or relationships with ASN Task Force on eGFR and Race, Centers for Medicare & Medicaid Services Technical Expert Panel on Development of a Quality Measure Assessing Delay in Progression of Chronic Kidney Disease (CKD), NKF, and Technical Expert Panel for Quality Insights Kidney Care Pilot project.

Comment on

References

    1. Baigent C Emberson J Haynes R, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–1801. doi: 10.1016/s0140-6736(22)02074-8 - DOI - PMC - PubMed
    1. Rossing P Caramori ML Chan JC, et al. KDIGO 2022 clinical Practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5):S1–S127. doi: 10.1016/j.kint.2022.06.008 - DOI - PubMed
    1. Chertow GM Vart P Jongs N, et al. Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol. 2021;32(9):2352–2361. doi: 10.1681/ASN.2021020167 - DOI - PMC - PubMed
    1. Adhikari R Jha K Dardari Z, et al. National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc. 2022;11(9):e023811. doi: 10.1161/jaha.121.023811 - DOI - PMC - PubMed
    1. Farxiga (dapagliflozin) package insert. Astrazeneca Pharmaceuticals LP. Revised May 2023. Accessed June 23, 2023. https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b18....

MeSH terms

Substances